Certara, Inc.

CERT

$7.95

-2.26%

2026-09-04 09:49:03 EDT-$0.18

Healthcare

Medical - Healthcare Information Services

NASDAQ

Active Trading

Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery ...

Price Action of CERT

$7.95

-2.26%-$0.18

High—

Low—

52W High-42.7%

Rel. vol—

Interval

Range18m

Volume—SMA5SMA10

—

Certara, Inc. is a global biosimulation company founded in 2008 and headquartered in Radnor, Pennsylvania. It provides advanced software and technology-driven services to optimize drug development across the entire lifecycle, from discovery and preclinical research to clinical trials, regulatory submissions, and market access. The company's core mission is to accelerate ...Certara, Inc. is a global biosimulation company founded in 2008 and headquartered in Radnor, Pennsylvania. It provides advanced software and technology-driven services to optimize drug development across the entire lifecycle, from discovery and preclinical research to clinical trials, regulatory submissions, and market access. The company's core mission is to accelerate the delivery of new medicines to patients by transforming traditional processes with biosimulation software and expertise. Its portfolio includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, regulatory writing and communications, and market access consultation. Certara's software platforms cover PK/PD biosimulation, data standardization, regulatory submission authoring, and market access communication. The company serves biopharmaceutical firms, academic institutions, and government organizations. With over 1,515 employees and operations in more than 30 countries, Certara maintains a significant global presence. Key financial metrics indicate a market cap of approximately $1.28 billion, with a focus on revenue generation despite recent net losses. The founding CEO was Jon Resnick, who has been leading the company toward innovation in model-informed drug development. Certara is publicly traded on NASDAQ under the symbol CERT and continues to expand its technological capabilities, as evidenced by initiatives like Certara.AI, which applies artificial intelligence to drug discovery and regulatory processes.ExpandCollapse

Founded

2008

Employees

1546

CEO

Jon Resnick

Full Name

Certara, Inc.

Sector

Healthcare

Industry

Medical - Healthcare Information Services

ROE

-6.66%

Market Cap

$1.24B

Current Ratio

2.55

WACC

12.11%

ROIC

2.76%

Contact Information

https://www.certara.com

609 716 7900

4 Radnor Corporate Center, Radnor, PA 19087

Key Metrics of CERT

Snapshot

Latest / TTM · 6 periods

Market Cap

$1.24B

ROCE

0.6%

EV / EBITDA

16.13x

-0.9% YoY

FCF Yield

5.0%

+0.0% YoY

Cash Conversion Cycle

95.9d

Current Ratio

2.55

Quick take

TTM —

Positive CCC

Financial Highlights of CERT

Profitability trend

Latest / TTM · 6 periods

Gross Margin

58.3%

Net Margin

-16.7%

P/E Ratio

-17.92x

n/a

Debt / Equity

0.30

n/a

Current Ratio

2.55

Dividend Yield

0.0%

Understanding

TTM —

No major balance sheet stress in these headline ratios.

Calendar of CERT

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $0.09 · Revenue $92.75M · 6 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $0.09 · Revenue $94.54M · 6 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $0.34 · Revenue $380.10M · 6 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $0.11 · Revenue $96.70M · 2 analysts

Recent history

Aug 4, 2026
Q2 FY2026 · Results reported
EPS $-0.36 · Revenue $93.27M
View filing
May 11, 2026
Q1 FY2026 · Results reported
EPS $-0.06 · Revenue $106.92M
View filing
Feb 26, 2026
FY2025 · Annual results
EPS $-0.01 · Revenue $418.84M
View filing
Nov 6, 2025
Q3 FY2025 · Results reported
EPS $0.01 · Revenue $104.62M
View filing
Aug 6, 2025
Q2 FY2025 · Results reported
EPS $-0.01 · Revenue $104.57M
View filing
May 5, 2025
Q1 FY2025 · Results reported
EPS $0.03 · Revenue $106.00M
View filing

Financial Statements of CERT

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$418.8M	+8.7%	-12.8%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-1.6M	+86.8%	-530.7%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+61.5%	+2.8%	+31.4%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+5.0%	+1216.4%	-105.7%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-0.4%	+87.8%	-623.0%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$69.8M	+17.4%	+91.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+16.7%	+8.0%	+119.7%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	1.1%	-96.4%	+2.3%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	2.05x	-3.4%	+35.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$1.6B	-1.2%	-6.7%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.01 vs 0.46	-102.2%	-0.36 vs 0.09	-505.1%
Revenue Surprise	$418.8M vs $418.1M	+0.2%	$93.3M vs $92.8M	+0.6%

Insider Transactions of CERT

Acquisitions (A)

Since Jun 1, 2026

Disposals (D)

Since Jun 1, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Sep 1, 2026	Mohammed Faiz	officer: Interim CFO	Restricted Stock Units	A	63,532	—
Jul 15, 2026	Mohammed Faiz	officer: Interim CFO	Common Stock	—	0	—
Jul 15, 2026	Mohammed Faiz	officer: Interim CFO	Restricted Stock Units	—	13,290	—
Jul 15, 2026	Mohammed Faiz	officer: Interim CFO	Performance Stock Units	—	8,544	—
Jun 1, 2026	Anhalt Rona	officer: Chief Human Resources Officer	Common Stock	A	7,147	—

Earnings Call Transcript of CERT

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Good day, and thank you for standing by. Welcome to the Certara Second Quarter 2026 Earnings Conference Call. [Operator Instructions]. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Jay Liu, Investor Relations at LifeSci. Please go ahead. Jay Liu: Good morning, everyone. Thank you all for participating in today's conference call. On the call from Certara, we have Jon Resnick, Chief Executive Officer; and Faiz Mohammed, Interim Chief Financial Officer. Earlier today, Certara released financial results for the quarter ended June 30, 2026. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements, and actual results may differ materially from those expressed or implied in the forward-looking statements. Please refer to Slide 2 in the accompanying presentation titled Second Quarter 2026 Financial Results for additional information, which you can find on the company's Investor Relations website. In their remarks or responses to questions, management may mention some non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are available in the recent earnings press release available on the company's website. Please refer to the reconciliation tables in the accompanying materials for additional information. This conference call contains time-sensitive information and is accurate only as of today, August 4, 2026. Certara disclaims any obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. And with that, I will turn the call over to Jon. Jon Resnick: Thank you for joining today's call. Before I get into our results, I want to highlight the appointment of our new Chief Commercial Officer, which we announced earlier this morning. This reflects our commitment to a new, more impactful go-to-market approach, which I'll cover in more detail shortly. The second quarter was about executing on our commitments. Overall, we are pleased with our progress. We are transforming Certara into a company we believe is capable of delivering sustainable double-digit growth. We still have work to do, but we are on the right path. We are executing against our plan. Our foundation is strengthening and the macro market conditions, biopharma spending, clinical trial starts and new regulatory guidance continue to be in our favor. I'll start with our top line financials, then move to our strategic and operational priorities, our client impact and finally, how we are leveraging AI. Top line results in the quarter were in line with expectations and guidance. Overall, revenue growth was modest at 1% with software revenue growing 4% and service revenue declining 3%. On software, …

Leadership Team of CERT

14 executives

Name	Title	Compensation	Gender	Year Born	Status
Jon Resnick	Chief Executive Officer & Director	USD 1,404,299	Male	1973	Active
Adrian K. McKemey	President of Drug Development Solutions	USD 1,075,132	—	—	Active
John E. Gallagher	SVP, Principal Accounting Officer & Chief Financial Officer	USD 924,248	Male	1973	Active
Robert Aspbury	President of Certara Predictive Technologies	USD 826,125	—	1972	Active
Julien Perrier	President & Chief Commercial Officer	USD 690,082	Male	—	Active
Leif E. Pedersen	Senior Advisor	USD 690,082	Male	1965	Active
Faiz Mohammed	Interim CFO, Senior VP of Finance, Treasurer and Principal Financial & Accounting Officer	—	Male	1973	Active
Eric Jahn	Chief Information Officer	—	—	—	Active
Martin Snyder	President of Certara Data Sciences	—	Male	—	Active
Rona Anhalt	Chief Human Resources Officer	—	Female	1965	Active
Sheila Rocchio	Chief Marketing Officer	—	Female	—	Active
Christopher Bouton	Chief Technology Officer & Chief AI Officer	—	—	—	Active
Ron DiSantis	Senior Vice President of Corporate Development	—	Male	—	Active
Daniel Corcoran	Senior Vice President, General Counsel & Secretary	—	Male	1967	Active

Recent News of CERT

Seeking Alpha8/4/2026Neutral

Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript

MarketBeat8/4/2026Neutral

Certara Q2 Earnings Call Highlights

Certara NASDAQ: CERT reported second-quarter 2026 revenue of $93.3 million, up 1% year over year, as software growth offset a decline in services revenue. Management reaffirmed its full-year revenue outlook while outlining further changes to its commercial organization, cost structure and artificial intelligence strategy.

Zacks Investment Research8/4/2026Neutral

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

Certara, Inc. (CERT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.

GlobeNewsWire8/4/2026Neutral

Certara Reports Second Quarter 2026 Financial Results

Appoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 revenue guidance RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its second quarter 2026 financial results.

PRNewsWire7/23/2026Neutral

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Historical Employee Count of CERT

Current

1,515

Change

+1.88%

Minimum

1,054

Maximum

1,515

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	1,515	10-K	Feb 26, 2026	View
Dec 31, 2024	1,487	10-K	Feb 26, 2025	View
Dec 31, 2023	1,338	10-K	Feb 29, 2024	View
Dec 31, 2022	1,150	10-K	Mar 1, 2023	View
Dec 31, 2021	1,054	10-K	Mar 1, 2022	View

Related stocksMedical - Healthcare Information Services

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Certara, Inc.